EyeGate Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
August 10, 2016 16:50 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 10, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on...
EyeGate Announces Positive Top-line Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Post-Operative Inflammation and Pain in Cataract Surgery Patients
August 01, 2016 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Announces Completion of $3.77 Million Registered Direct Offering
June 30, 2016 13:00 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., June 30, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Announces $3.77 Million Registered Direct Offering
June 27, 2016 08:00 ET
|
Eyegate Pharmaceuticals, Inc.
WALTHAM, Mass., June 27, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Announces Encouraging Interim Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Ocular Inflammation and Pain Post Cataract Surgery
June 01, 2016 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Pharma Announces At The Market Issuance Program
May 24, 2016 18:00 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., May 24, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (the “Company”) announced today that it has entered into an At The Market Issuance ("ATM") Sales...
Eyegate Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update
May 13, 2016 17:25 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., May 13, 2016 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Pharma Appoints Dr. Brenda K. Mann as Vice President, Research and Development
May 06, 2016 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., May 06, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Pharma Appoints Ryan R. Brenneman as Chief Financial Officer
April 27, 2016 16:05 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., April 27, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Pharma to Present Four Posters at ARVO 2016 Annual Meeting Supporting Development of CMHA-S
April 26, 2016 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., April 26, 2016 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...